Asceneuron’s tau modifier receives Orphan Drug Designation
Posted on 20.07.2018 in Company Highlight, News
20.7.2018 The US Food and Drug Administration has granted Orphan Drug Designation to Asceneuron’s ASN120290 for the treatment of progressive supranuclear palsy, a rapidly progressing rare neurodegenerative disorder. The molecule has the potential to become a first in class treatment for PSP and other tau-related dementias.
